MeiraGTx is a clinical-stage genetic medicines company developing targeted therapies using proprietary viral vectors and gene regulation technologies to treat inherited and common diseases with severe unmet needs. The company operates vertically integrated GMP-compliant manufacturing facilities to produce its own viral vectors and plasmids, supporting internal end-to-end development and manufacturing at reduced costs and dosing. Its clinical pipeline spans ophthalmology, neurodegeneration, and other therapeutic areas, with revenue generated through milestone and royalty payments from licensing agreements and collaborations with larger pharmaceutical partners.